William Derosa, DO
Hematology & Oncology · Morristown, NJNPI 1902894991
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,000 of the $14,942 with a category attached, or 73.6%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 89.9% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $14,190 and has fallen 96.5% since, to $490 in 2023.
Across 52 payments — averaging $287.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$13K
- Janssen Research & Development, LLC$461
- Daiichi Sankyo Inc.$165
- Novartis$131
- Bristol Myers Squibb$127
- Genmab U.S., Inc.$115
- plus $509 from 15 others
Across 43 payments — averaging $3855.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$84K
- Bristol Myers Squibb$50K
- Janssen Research & Development, LLC$16K
- E.r. Squibb & Sons, L.L.C.$16K
- Eli Lilly$198
What the payments were for
- Speaking & faculty fees$11,00074%
- Travel & lodging$2,39716%
- Food & beverage$1,42010%
- Education$1261%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $13,435 |
| Janssen Research & Development, LLC | 5 | $461 |
| Daiichi Sankyo Inc. | 1 | $165 |
| Novartis | 4 | $131 |
| Bristol Myers Squibb | 2 | $127 |
| Genmab U.S., Inc. | 1 | $115 |
| Incyte Corporation | 1 | $99 |
| Seagen Inc. | 4 | $56 |
| AstraZeneca | 4 | $54 |
| Myriad Genetic Laboratories, Inc. | 1 | $38 |
| Sirtex Medical Inc | 2 | $36 |
| Eisai Inc. | 2 | $30 |
| Bayer | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Merck | 2 | $28 |
| Gilead | 2 | $27 |
| Pfizer | 2 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Sanofi | 1 | $15 |
| EMD Serono, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,942 in reported general payments places this provider in the 80th percentile of 362 hematology & oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 47 | $691,016 |
| RevlimidLenalidomide | 19 | $366,610 |
| CalquenceAcalabrutinib Maleate | 20 | $298,769 |
| IbrancePalbociclib | 18 | $286,472 |
| PomalystPomalidomide | 12 | $265,159 |
| Lenalidomide | 17 | $235,393 |
| VenclextaVenetoclax | 24 | $228,113 |
| BrukinsaZanubrutinib | 13 | $193,212 |
| Imatinib Mesylate | 23 | $96,229 |
| EliquisApixaban | 67 | $52,866 |
| CreonLipase/Protease/Amylase | 12 | $44,022 |
| XareltoRivaroxaban | 24 | $17,300 |
| Famciclovir | 28 | $2,142 |
| Anastrozole | 24 | $863 |
| Hydroxyurea | 27 | $838 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $99 | $691,01647 claims |
| Bristol Myers SquibbRevlimid | $127 | $366,61019 claims |
| PfizerIbrance, Eliquis | $26 | $339,33885 claims |
| AstraZenecaCalquence | $54 | $298,76920 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $29 | $265,15912 claims |
| Johnson & JohnsonXarelto | $14 | $17,30024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 362 hematology & oncology providers in New Jersey.
Other hematology & oncology in Morristown
- Charles FarberMorristown$609K
- Michael ScolaMorristown$506K
- Mohamad CherryMorristown$240K
- Robert SpiegelWestfield$864K
- Amit PatelJersey City$770K
- Joshua StraussSpringfield$739K
- Eshan PatelSomerville$420K
- Arturo Loaiza-BonillaPennington$406K
- Ashish ShahSpringfield$394K
- Carl HenningsonManasquan$349K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.